Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Cancer Antibody Drug Conjugates market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.5% during the forecast period.
This report presents the market size and development trends by detailing the Cancer Antibody Drug Conjugates market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Cancer Antibody Drug Conjugates market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Cancer Antibody Drug Conjugates industry and will help you to build a panoramic view of the industrial development.
Cancer Antibody Drug Conjugates Market, By Type:
First & Second Generation ADCs
Third Generation ADCs
Cancer Antibody Drug Conjugates Market, By Application:
Hospitals
Clinics
Other
Some of the leading players are as follows:
AbbVie
Stem CentRx
Biotest AG
Seattle Genetics
Helix BioPharma
Novartis
Nordic Nanovector
AbGenomics Corporation
UCB
Viventia Biotechnologies
Bristol-Myers Squibb
PDL BioPharma
Merck
Progenics Pharmaceuticals
Biogen Idec
Millennium
Roche
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Cancer Antibody Drug Conjugates Market: Technology Type Analysis
-
4.1 Cancer Antibody Drug Conjugates Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Cancer Antibody Drug Conjugates Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 First & Second Generation ADCs
4.3.2 Third Generation ADCs
5 Cancer Antibody Drug Conjugates Market: Product Analysis
-
5.1 Cancer Antibody Drug Conjugates Product Market Share Analysis, 2018 & 2026
-
5.2 Cancer Antibody Drug Conjugates Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Cancer Antibody Drug Conjugates Market: Application Analysis
-
6.1 Cancer Antibody Drug Conjugates Application Market Share Analysis, 2018 & 2026
-
6.2 Cancer Antibody Drug Conjugates Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Other
7 Cancer Antibody Drug Conjugates Market: Regional Analysis
-
7.1 Cancer Antibody Drug Conjugates Regional Market Share Analysis, 2018 & 2026
-
7.2 Cancer Antibody Drug Conjugates Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 AbbVie
9.1.1 AbbVie Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Stem CentRx
9.2.1 Stem CentRx Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Biotest AG
9.3.1 Biotest AG Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Seattle Genetics
9.4.1 Seattle Genetics Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Helix BioPharma
9.5.1 Helix BioPharma Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Novartis
9.6.1 Novartis Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Nordic Nanovector
9.7.1 Nordic Nanovector Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 AbGenomics Corporation
9.8.1 AbGenomics Corporation Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 UCB
9.9.1 UCB Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Viventia Biotechnologies
9.10.1 Viventia Biotechnologies Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Bristol-Myers Squibb
9.11.1 Bristol-Myers Squibb Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 PDL BioPharma
9.12.1 PDL BioPharma Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Merck
9.13.1 Merck Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Progenics Pharmaceuticals
9.14.1 Progenics Pharmaceuticals Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Biogen Idec
9.15.1 Biogen Idec Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Millennium
9.16.1 Millennium Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Roche
9.17.1 Roche Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
The List of Tables and Figures (Totals 60 Figures and 144 Tables)
Figure First & Second Generation ADCs Cancer Antibody Drug Conjugates market, 2015 - 2026 (USD Million)
Figure Third Generation ADCs Cancer Antibody Drug Conjugates market, 2015 - 2026 (USD Million)
Figure Hospitals market, 2015 - 2026 (USD Million)
Figure Clinics market, 2015 - 2026 (USD Million)
Figure Other market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Cancer Antibody Drug Conjugates market, by country, 2015 - 2026 (USD Million)
-
Table North America Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table North America Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table North America Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Canada Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Canada Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Europe Cancer Antibody Drug Conjugates market, by country, 2015 - 2026 (USD Million)
-
Table Europe Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Europe Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Europe Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Germany Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Germany Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table France Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table France Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Italy Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Italy Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Spain Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Spain Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Antibody Drug Conjugates market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table China Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table China Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Japan Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Japan Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table India Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table India Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Antibody Drug Conjugates market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table MEA Cancer Antibody Drug Conjugates market, by country, 2015 - 2026 (USD Million)
-
Table MEA Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table MEA Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table MEA Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Cancer Antibody Drug Conjugates market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Antibody Drug Conjugates market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Antibody Drug Conjugates market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table AbbVie Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Stem CentRx Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biotest AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Seattle Genetics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Helix BioPharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Nordic Nanovector Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AbGenomics Corporation Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table UCB Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Viventia Biotechnologies Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table PDL BioPharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Progenics Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biogen Idec Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Millennium Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
